Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:10:50 2026-06-16 EDT			5-day change	1st Jan Change
119.99 ^CHF	-0.19%		+1.25%	+9.36%

06-15	Global drugmakers invest billions to boost US presence	RE
06-12	Analyst recommendations: Adobe, CME Group, Nvidia, Flutter…

Novartis target price raised after upgrades

Following strong execution and two 2025 outlook upgrades, the analyst lifts estimates and raises the target price, citing high-margin growth areas, robust R&D, disciplined bolt-on acquisition strategy, and solid balance sheet support to sustain mid-term ambitions.

Published on 12/05/2025 at 11:23 am EST - Modified on 12/05/2025 at 10:49 am EST

Alphavalue

Novartis target price raised after upgrades

This article is reserved for subscribers.

Alphavalue, the European leader in independent research, is exclusively available on MarketScreener.

To unlock the article, subscribe!

Latest news about Novartis AG

06-15	Global drugmakers invest billions to boost US presence	RE
06-12	Analyst recommendations: Adobe, CME Group, Nvidia, Flutter…
06-12	Novartis' Rhapsido Meets Primary Endpoints in Chronic Inducible Urticaria Trial	MT
06-12	Novartis RemIND data at EAACI show Rhapsido(R) potential as first targeted therapy for chronic inducible urticaria (CIndU)	DJ
06-12	Novartis AG Presents RemIND Data At EAACI Demonstrating Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria	CI
06-12	Swiss stocks - Factors to watch on June 12	RE
06-12	Swiss pharma hub Basel frets over population cap threat	RE
06-11	Novartis says rare muscle disease drug shows promise in early trial	RE
06-11	Swiss Blue-chip Index in Green as ECB Rate Decision Takes Center Stage	MT
06-11	European Stocks Close Higher in Thursday Trading; ECB Raises Interest Rates by 25 Basis Points	MT
06-11	US Equity Futures Rise Pre-Bell After US Says Strikes Completed Against Iran	MT
06-11	Novartis AG Announces Phase I/II Study Results For Delpacibart Braxlosiran In Facioscapulohumeral Muscular Dystrophy	CI
06-11	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid US Attacks on Iran	MT
06-11	Novartis Says Early-to-Mid Stage Study for Muscular Dystrophy Drug Meets Main Goal	MT
06-11	NOVARTIS AG : Jefferies remains Neutral	ZD

Chart Novartis AG

Duration

Period

NOVN: Dynamic Chart

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company